Sugi Predict

Sugi Predict / Compounds / SCHEMBL2224044

SCHEMBL2224044

SCHEMBL2224044

O=C(c1cc(Br)cs1)C(F)(F)F

nearest known ligand 0.59

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ CES1 P23141 2/20 0.59
▸ CES2 O00748 1/20 0.59
▸ HDAC6 Q9UBN7 12/20 0.56
▸ ALDH1A1 P00352 2/20 0.50
▸ LMNA P02545 1/20 0.50
▸ GSK3B P49841 1/20 0.50
▸ HDAC4 P56524 5/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ ALAD P13716 1/20 0.38
▸ HDAC1 Q13547 6/20 0.35
▸ HDAC3 O15379 1/20 0.35
▸ DAO P14920 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24198721 0.79 CES2 (0.59) CES1CES2HDAC6ALDH1A1LMNA
SCHEMBL18830929 0.78 HDAC6 (0.54) CES1CES2HDAC6HDAC4HDAC1
SCHEMBL7253264 0.78 DAO (0.59) HDAC6HDAC4HDAC1HDAC3DAO
SCHEMBL24198793 0.77 CES2 (0.52) CES1CES2HDAC6ALDH1A1LMNA
SCHEMBL751818 0.76 GSK3B (0.56) CES1CES2HDAC6ALDH1A1LMNA
SCHEMBL26962842 0.75 CES2 (0.48) CES1CES2HDAC6ALDH1A1LMNA
SCHEMBL27623970 0.75 CES2 (0.73) CES1CES2ALDH1A1LMNAGSK3B
SCHEMBL425130 0.73 — —
SCHEMBL18430395 0.72 HDAC6 (0.49) HDAC6ALDH1A1HDAC4SMN1; SMN2
SCHEMBL3450 0.71 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12595239-B2 Substituted isoxazoline derivatives BASF SE (DE) 2026-04-07 — — US disclosed
US-20250346585-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2025-11-13 — — US disclosed
EP-4291551-B1 SUBSTITUTED ISOXAZOLINE DERIVATIVES BASF SE (DE) 2025-08-13 — — EP disclosed
US-20240140917-A1 SUBSTITUTED ISOXAZOLINE DERIVATIVES BASF SE (DE) 2024-05-02 — — US disclosed
EP-4291551-A1 SUBSTITUTED ISOXAZOLINE DERIVATIVES BASF SE (DE) 2023-12-20 — — EP disclosed
WO-2023183405-A2 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2023-09-28 — — WO disclosed
WO-2022171472-A1 SUBSTITUTED ISOXAZOLINE DERIVATIVES BASF SE (DE) 2022-08-18 — — WO disclosed
US-9493485-B2 Spirocyclic dihydro-thiazine and dihydro-oxazine BACE inhibitors, and compositions and uses thereof IMAGO PHARMACEUTICALS, INC. (US) 2016-11-15 — — US disclosed
US-9493485-B2 Spirocyclic dihydro-thiazine and dihydro-oxazine BACE inhibitors, and compositions and uses thereof IMAGO PHARMACEUTICALS, INC. (US) 2016-11-15 — — US disclosed
US-20160272654-A1 SPIROCYCLIC DIHYDRO-THIAZINE AND DIHYDRO-OXAZINE BACE INHIBITORS, AND COMPOSITIONS AND USES THEREOF IMAGO PHARMACEUTICALS, INC. (US) 2016-09-22 — — US disclosed
US-8901156-B2 Compounds and methods TEMPERO PHARMACEUTICALS, INC. (US) 2014-12-02 — — US disclosed
WO-2013142613-A1 SPIROCYCLIC DIHYDRO-THIAZINE AND DIHYDRO-OXAZINE BACE INHIBITORS, AND COMPOSITIONS AND USES THEREOF ELAN PHARMACEUTICALS, INC. (US) 2013-09-26 — — WO disclosed
US-20130059883-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. 2013-03-07 — — US disclosed
US-20130059883-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. 2013-03-07 — — US disclosed
US-20130059883-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. 2013-03-07 — — US disclosed
WO-2011088181-A9 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. (US) 2013-01-31 — — WO disclosed
WO-2011088181-A9 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. (US) 2013-01-31 — — WO disclosed
EP-2533783-A1 COMPOUNDS AND METHODS Tempero Pharmaceuticals, Inc. (US) 2012-12-19 — — EP disclosed
WO-2011088181-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. (US) 2011-07-21 — — WO disclosed
WO-2011088181-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. (US) 2011-07-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12595239-B2 Substituted isoxazoline derivatives CBR3, ADRA2C, CYP4Z1 CES1 606/4885CES2 403/4885HDAC6 1335/4885
US-20240140917-A1 SUBSTITUTED ISOXAZOLINE DERIVATIVES CYP4X1, PRDX5, PRDX1 CES1 3087/4885CES2 1811/4885HDAC6 404/4885
US-20250346585-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS C5, C1S, C9 CES1 413/4885CES2 1957/4885HDAC6 3404/4885
US-20130059883-A1 COMPOUNDS AND METHODS XDH, LPXN, CCNY CES1 808/4885CES2 94/4885HDAC6 1474/4885
US-20160272654-A1 SPIROCYCLIC DIHYDRO-THIAZINE AND DIHYDRO-OXAZINE BACE INHIBITORS, AND COMPOSITIONS AND USES THEREOF BACE1, BACE2, APP CES1 623/4885CES2 2237/4885HDAC6 893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.